Latest research offer hope of cure for Fuchs' corneal dystrophy

Researchers in Japan have demonstrated an effective cell based cure for Fuchs' corneal dystrphy which may be available for patients within a decade if results from clinical trials are successful. The trial which was performed in a primate monkey model of Fuchs' dystrophy shows complete clearing of swollen corneas after cell treatment.

Fuchs dystrophy cure

Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction.

Okumura N1Sakamoto Y2Fujii K1Kitano J1Nakano S1Tsujimoto Y1Nakamura S3Ueno M4Hagiya M4Hamuro J4Matsuyama A5Suzuki S6Shiina T6Kinoshita S4,7Koizumi N1.

Author information

Abstract

The corneal endothelium maintains corneal transparency; consequently, its dysfunction causes severe vision loss. Tissue engineering-based therapy, as an alternative to conventional donor corneal transplantation, is anticipated to provide a less invasive and more effective therapeutic modality. We conducted a preclinical study for cell-based therapy in a primate model and demonstrated regeneration of the corneal endothelium following injection of cultured monkey corneal endothelial cells (MCECs) or human CECs (HCECs), in combination with a Rho kinase (ROCK) inhibitor, Y-27632, into the anterior chamber. We also evaluated the safety and efficacy of Good Manufacturing Practice (GMP)-grade HCECs, similar to those planned for use as transplant material for human patients in a clinical trial, and we showed that the corneal endothelium was regenerated without adverse effect. We also showed that CEC engraftment is impaired by limited substrate adhesion, which is due to actomyosin contraction induced by dissociation-induced activation of ROCK/MLC signaling. Inclusion of a ROCK inhibitor improves efficiency of engraftment of CECs and enables cell-based therapy for treating corneal endothelial dysfunction as a clinically relevant therapy.

 

Posted on June 5, 2016 .